Trial Profile
A Pilot Study Assessing the Safety and Efficacy of Pioglitazone as an Anti-inflammatory Agent for the Treatment of CF Lung Disease in Patients With Cystic Fibrosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Pioglitazone (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 14 Oct 2014 New trial record